---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-17T23:28:16.413836'
end_time: '2025-12-17T23:36:52.672010'
duration_seconds: 516.26
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Osteoporosis
  mondo_id: ''
  category: Complex
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 17
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Osteoporosis
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Osteoporosis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Osteoporosis
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Osteoporosis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Plan
- Objective 1 (completed): Defined scope and prioritized recent (2023–2024) mechanisms and authoritative reviews.
- Objective 2 (completed): Searched literature for core pathways (RANKL/RANK/OPG; Wnt/β‑catenin–sclerostin; estrogen deficiency; osteoimmunology; oxidative stress/Nrf2/FOXO/SIRT; senescence; MSC adipogenic shift; mechanotransduction; gut–bone axis; denosumab rebound).
- Objective 3 (completed): Extracted evidence, mechanistic statements, and quotes with URLs/dates.
- Objective 4 (completed): Organized evidence into knowledge-base structure (genes, GO/CL/UBERON/CHEBI mapping).
- Objective 5 (completed): Created artifact summarizing key mechanisms with ontology and citations.
- Objective 6 (completed): Wrote comprehensive, well‑cited report with 2023–2024 emphasis.
- Objective 7 (completed): Submit final answer with inline citations.

Disease Pathophysiology Research Report

Target Disease
- Disease Name: Osteoporosis
- MONDO ID: MONDO:0005292
- Category: Complex

Pathophysiology description
Osteoporosis is driven by chronic imbalance in bone remodeling: increased osteoclast-mediated resorption relative to osteoblast-mediated formation, with osteocytes as mechanosensory regulators orchestrating both arms. Osteoclastogenesis is initiated when RANKL (TNFSF11) on osteoblast-lineage cells and osteocytes engages RANK (TNFRSF11A) on myeloid precursors; OPG (TNFRSF11B) acts as a soluble decoy receptor to limit this interaction. Estrogen deficiency, inflammaging, oxidative stress, cellular senescence, disrupted mechanotransduction, a bias of bone marrow mesenchymal stem cells (BMSCs) toward adipogenesis, and gut–immune dysregulation converge to enhance RANKL/M‑CSF signaling and suppress osteoanabolic Wnt/β‑catenin pathways (notably via osteocyte‑derived sclerostin/DKK1), producing trabecular and cortical bone loss and microarchitectural deterioration (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).

| Mechanism / Pathway | Key genes / proteins (HGNC) | Cell types (CL terms where applicable) | Cellular components (GO-CC) | Anatomical locations (UBERON) | Mechanistic notes | Evidence (context IDs) and Year |
|---|---|---|---|---|---|---|
| RANKL / RANK / OPG axis | TNFSF11 (RANKL), TNFRSF11A (RANK), TNFRSF11B (OPG) | Osteoblasts (CL:0000064), osteocytes (CL:0000182), osteoprogenitors | Extracellular region (GO:0005615); plasma membrane (GO:0005886) | Trabecular bone surface (UBERON:0002371); cortical bone (UBERON:0002807) | Osteoblast/osteocyte-derived RANKL binds RANK on osteoclast precursors to drive osteoclastogenesis; OPG is a soluble decoy limiting RANKL activity; dysregulation → increased resorption. | (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6) 2024 / 2025 |
| Wnt / β-catenin — sclerostin / DKK1 regulation | SOST (sclerostin), DKK1, CTNNB1 (β-catenin), LRP5/6 | Osteocytes (major SOST source), osteoblasts | Extracellular region (GO:0005615); nucleus (GO:0005634) | Bone (UBERON:0000104) | Osteocyte-secreted sclerostin and DKK1 antagonize Wnt → ↓β-catenin signaling and osteoblast differentiation; anti-sclerostin therapy (romosozumab) is anabolic. | (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6) 2024 / 2025 |
| Estrogen deficiency & pro‑inflammatory cytokines | ESR1, TNF (TNF), IL1B, IL6, IL17A, TNFSF11 (RANKL) | Th17 cells (CL:0000739), Tregs (CL:0000810), B cells, osteoblasts, osteocytes | Extracellular region (GO:0005615); receptor complex (GO:0043235) | Postmenopausal bone, bone marrow (UBERON:0002371) | Loss of estrogen increases TNF‑α, IL‑1, IL‑6 and IL‑17 → upregulates RANKL/M‑CSF, suppresses OPG and promotes osteoclastogenesis and bone resorption. | (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 25-26) 2025 / 2024 |
| Oxidative stress — Nrf2 / FOXO / SIRT axis | NFE2L2 (Nrf2), KEAP1, FOXO1/3, SIRT1, SIRT3 | Osteoblasts, osteocytes, BMSCs (mesenchymal stem cells) | Mitochondrion (GO:0005739); nucleus (GO:0005634) | Bone marrow (UBERON:0002371); bone tissue | Excess ROS impairs osteoblastogenesis, induces apoptosis and activates NF‑κB-driven osteoclastogenesis; Nrf2/Keap1 is protective; SIRT/FOXO and SIRT3 support mitochondrial function and antioxidant responses. | (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 25-26) 2025 / 2024 |
| Cellular senescence and SASP | CDKN2A (p16INK4a), TP53, IL6, IL8, MMPs | Senescent osteocytes, senescent osteoblasts, senescent BMSCs | Secretory vesicle (GO:0099503); extracellular region (GO:0005615) | Bone tissue, lacuno‑canalicular network (UBERON:0002106) | Accumulation of senescent bone cells secretes SASP (IL‑6, IL‑8, proteases) that drive local inflammation, increase osteoclast activity and impair bone formation; senolytic clearance preserves bone in models. | (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 25-26) 2025 / 2024 |
| BMSC lineage shift → marrow adiposity | RUNX2, PPARG (PPARγ), CEBPA | Bone marrow mesenchymal stem cells (BMSCs) | Nucleus / chromatin (GO:0005634 / GO:0000785) | Bone marrow (UBERON:0002371) | Aging, oxidative stress or glucocorticoids downregulate RUNX2 and upregulate PPARγ → BMSC adipogenic differentiation at expense of osteoblastogenesis, increasing marrow fat and reducing bone formation. | (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8) 2025 / 2025 |
| Osteocyte mechanotransduction (sclerostin; Piezo1) | SOST (sclerostin), PIEZO1 | Osteocytes (CL:0000182) | Plasma membrane (GO:0005886); lacuno‑canalicular network (GO:0120027) | Cortical and trabecular bone (UBERON:0002807 / UBERON:0002371) | Mechanical loading suppresses sclerostin and promotes Wnt signaling; Piezo1 acts as a mechanosensor in osteocytes—mechanical unloading increases sclerostin and RANKL, promoting resorption. | (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6) 2024 / 2025 |
| Gut microbiome → bone axis (Th17 / Treg; SCFAs) | IL17A, FOXP3, WNT10B (induced), microbial metabolites (butyrate) | Intestinal epithelial cells, Th17 (CL:0000739), Treg (CL:0000810) | Extracellular region; microbial metabolite compartment | Gut (UBERON:0002107) → bone marrow (UBERON:0002371) | SCFAs (e.g., butyrate) promote Treg differentiation, suppress osteoclastogenesis and can stimulate Wnt10b via Treg→CD8+ axis; dysbiosis shifts Th17/Treg balance increasing RANKL and bone loss; human RCTs show mixed effects on BMD. | (zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 4-6) 2025 / 2025 |
| Denosumab discontinuation (rebound) — RANKL / OPG source mapping | TNFSF11 (RANKL), TNFRSF11B (OPG) | Bone‑surface osteoprogenitors, osteocytes, osteoblasts | Extracellular region (GO:0005615); plasma membrane (GO:0005886) | Trabecular bone surface; endocortical surface (UBERON:0002371 / UBERON:0002807) | Anti‑RANKL therapy (denosumab) suppresses resorption, but discontinuation is followed by rapid rebound resorption due to accumulated RANKL‑expressing bone surface cells and reduced local OPG expression (readily recruits osteoclasts). | (elahmer2024mechanisticinsightsand pages 25-26, elahmer2024mechanisticinsightsand pages 1-2) 2024 / 2024 |


*Table: Concise reference table mapping major molecular/cellular mechanisms in osteoporosis with key genes, cells, subcellular locations, anatomical sites, short mechanistic notes, and the context evidence IDs (pqac‑...) plus publication years used to build the summary.*

1) Core Pathophysiology
- Primary mechanisms
  - Excess osteoclastogenesis via RANKL/RANK with insufficient OPG: “OPG…competes with RANK to bind RANKL, thereby limiting osteoclastogenesis.” Osteocytes can regulate osteoclasts via RANKL (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 2-4).
  - Suppressed osteoblastogenesis via Wnt antagonism: osteocytes secrete sclerostin (SOST) and DKK1 to inhibit Wnt/β‑catenin, curtailing formation; PTH suppresses sclerostin to enable Wnt-driven bone formation (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3).
  - Estrogen deficiency drives pro‑inflammatory cytokines (TNF‑α, IL‑1, IL‑6; IL‑17 from Th17 cells), which increase RANKL/M‑CSF and reduce OPG, accelerating osteoclast maturation and resorption (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).
  - Oxidative stress/Nrf2–FOXO–SIRT axis: Excess ROS impairs osteoblastogenesis and promotes osteoblast/osteocyte apoptosis while activating NF‑κB–c‑Fos–NFATc1 osteoclast programs; the Nrf2/Keap1/ARE pathway is protective. Aging shifts BMSCs toward adipogenesis via ↑PPARγ2 and ↓RUNX2/Dlx5 (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6).
  - Cellular senescence/SASP: Senescent bone cells secrete IL‑6/IL‑8 and proteases that enhance resorption and impair formation; “eliminating senescent cells or inhibiting SASP preserves trabecular and cortical mass” (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6).
  - Mechanotransduction failure: Unloading increases osteocyte sclerostin and RANKL, tipping remodeling toward resorption; loading suppresses sclerostin and promotes Wnt signaling (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3).
  - Gut–bone axis: SCFAs such as butyrate promote Treg differentiation and can restrain osteoclastogenesis; microbiome shifts alter Th17/Treg balance and bone turnover (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 6-8).
- Molecular pathways dysregulated
  - RANKL/RANK/OPG; Wnt/β‑catenin (LRP5/6, β‑catenin) inhibited by sclerostin/DKK1; NF‑κB/MAPK downstream of inflammatory cytokines; Nrf2/Keap1 antioxidant signaling; PI3K/AKT/mTOR and JNK in oxidative stress responses; PPARγ-mediated adipogenesis (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).
- Cellular processes affected
  - Osteoclast differentiation/activation; osteoblast differentiation (RUNX2/OSX) and matrix mineralization; osteocyte viability and lacuno‑canalicular network signaling; BMSC fate choice between osteogenesis and adipogenesis; immune cell–bone crosstalk (Th17/Treg) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).

2) Key Molecular Players
- Genes/Proteins (HGNC)
  - TNFSF11 (RANKL), TNFRSF11A (RANK), TNFRSF11B (OPG) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4)
  - SOST (sclerostin), DKK1, CTNNB1 (β‑catenin), LRP5/6 (elahmer2024mechanisticinsightsand pages 2-3)
  - Cytokines: TNF, IL1B, IL6, IL17A (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4)
  - NFE2L2 (Nrf2), KEAP1, FOXO1/3, SIRT1/3 (zhao2025beyondboneloss pages 4-6)
  - RUNX2, SP7/OSX, PPARG (zhao2025beyondboneloss pages 4-6)
  - Cathepsin K, TRAP (osteoclast effector molecules) (elahmer2024mechanisticinsightsand pages 2-3)
- Chemical entities (CHEBI) and drugs
  - Denosumab (anti‑RANKL mAb), bisphosphonates, PTH analogs, anti‑sclerostin therapy (romosozumab) (elahmer2024mechanisticinsightsand pages 1-2, elahmer2024mechanisticinsightsand pages 2-3)
  - Reactive oxygen species (ROS) (CHEBI:26523) and antioxidants via Nrf2 pathway (zhao2025beyondboneloss pages 4-6)
- Cell types (CL)
  - Osteoclasts (CL:0000092), osteoblasts (CL:0000064), osteocytes (CL:0000182), BMSCs, Th17 (CL:0000739), Treg (CL:0000810) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8)
- Anatomical locations (UBERON)
  - Trabecular bone surface (UBERON:0002371), cortical bone (UBERON:0002807), bone marrow (UBERON:0002371), lacuno‑canalicular network (UBERON:0002106) (elahmer2024mechanisticinsightsand pages 2-3)

3) Biological Processes (GO terms) disrupted
- Osteoclast differentiation (GO:0030316); bone resorption (GO:0045453) via RANKL/RANK (elahmer2024mechanisticinsightsand pages 2-3)
- Osteoblast differentiation (GO:0001649), ossification (GO:0001503), Wnt signaling (GO:0016055) inhibited by sclerostin/DKK1 (elahmer2024mechanisticinsightsand pages 2-3)
- Response to oxidative stress (GO:0006979); Nrf2 signaling; activation of NF‑κB (GO:0007259) in osteoclastogenesis (zhao2025beyondboneloss pages 4-6)
- Regulation of inflammatory response (GO:0050727) including TNF/IL‑1/IL‑6/IL‑17 (zhao2025beyondboneloss pages 4-6)
- Cellular senescence and SASP (GO:0090398; secretory program) (zhao2025beyondboneloss pages 4-6)
- Regulation of cell differentiation toward adipocyte lineage (GO:0045598) via PPARγ (zhao2025beyondboneloss pages 4-6)
- Mechanosensory signaling (GO:0007165) in osteocytes; regulation of sclerostin (elahmer2024mechanisticinsightsand pages 2-3)

4) Cellular Components (GO-CC)
- Extracellular region (GO:0005615): RANKL, OPG, cytokines (elahmer2024mechanisticinsightsand pages 2-3)
- Plasma membrane (GO:0005886): RANK receptor; mechanosensors (general) (elahmer2024mechanisticinsightsand pages 2-3)
- Nucleus (GO:0005634): β‑catenin/TCF complexes; FOXO; Nrf2 (zhao2025beyondboneloss pages 4-6)
- Mitochondrion (GO:0005739): source of ROS; SIRT3 function (zhao2025beyondboneloss pages 4-6)
- Lacuno‑canalicular network (GO contextual to osteocytes): mechanotransduction (elahmer2024mechanisticinsightsand pages 2-3)

5) Disease Progression
- Initiating factors: estrogen decline, aging, glucocorticoids, unloading, dysbiosis → increased inflammatory cytokines and oxidative stress, impaired mechanotransduction (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4, elahmer2024mechanisticinsightsand pages 2-3).
- Early molecular changes: ↑RANKL/M‑CSF, ↓OPG; ↑sclerostin/DKK1; ROS accumulation; senescent cell accrual with SASP; BMSC fate shift to adipocytes (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 2-3).
- Cellular/structural outcomes: ↑osteoclast number/activity; ↓osteoblast differentiation and matrix mineralization; osteocyte apoptosis and LCN disruption; trabecular thinning and cortical porosity (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6).
- Clinical manifestation: decreased BMD, microarchitectural deterioration, fragility fractures; rebound bone loss upon abrupt denosumab discontinuation due to accumulated osteoclastogenic “activation sites” on bone surfaces with high RANKL and low OPG (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26).

6) Phenotypic Manifestations (HP terms)
- HP:0000939 (Osteoporosis), HP:0002818 (Pathologic fracture), HP:0002757 (Decreased bone mineral density) (linked to remodeling imbalance and Wnt suppression) (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).

Evidence items and selected direct quotes
- “OPG…competes with RANK to bind RANKL, thereby limiting osteoclastogenesis.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 2-4).
- “Osteocytes secrete sclerostin to inhibit Wnt signaling… PTH downregulates sclerostin to permit Wnt-driven formation.” URL: https://doi.org/10.3390/biomedicines12081635; Published: Jul 2024 (elahmer2024mechanisticinsightsand pages 2-3).
- “Oxidative stress… impairs bone formation by reducing osteoblastogenesis, increasing osteoblast and osteocyte apoptosis, and enhancing osteoclastogenesis… the Nrf2/Keap1/ARE axis is protective.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 4-6).
- “Cellular senescence and SASP… eliminating senescent cells or inhibiting SASP preserves trabecular and cortical mass.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 4-6).
- Denosumab rebound mechanism: “bone surface cells and osteocytes conjointly regulate the activation of osteoclastogenesis… OPG:Fc treatment induces a local accumulation of osteoclastogenic activation sites, ready to recruit and activate osteoclasts upon treatment discontinuation.” URL: https://doi.org/10.1038/s41413-024-00362-4; Published: Oct 2024 (elahmer2024mechanisticinsightsand pages 25-26).

Current applications and real‑world implementations (therapy–mechanism mapping)
- Anti‑resorptives: bisphosphonates (inhibit osteoclast function); denosumab (anti‑RANKL, suppresses osteoclastogenesis). Clinical caveat: denosumab discontinuation is associated with “extensive wave of rebound resorption” due to accumulated RANKL+ bone-surface activation sites and reduced local OPG—necessitating transition strategies (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26, elahmer2024mechanisticinsightsand pages 1-2).
- Anabolics: PTH analogs (intermittent PTH enhances formation, partly via downregulating sclerostin and activating Wnt); anti‑sclerostin (romosozumab) lifts Wnt inhibition to stimulate bone formation (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).
- Emerging mechanism‑targeted adjuncts: antioxidant/Nrf2‑targeting strategies; senolytics/SASP modulators; microbiome interventions to rebalance Th17/Treg and SCFAs—human RCT/meta‑analysis signals are mixed and require standardization of protocols (URLs: https://doi.org/10.3390/biomedicines13061443 Jun 2025; https://doi.org/10.3389/fendo.2024.1487998 Nov 2024) (zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 4-6).

Expert opinions and analysis
- Integrated osteoimmunology: Reviews emphasize immune–bone crosstalk regulating RANKL/OPG and the Th17/Treg axis as pivotal to postmenopausal bone loss, highlighting cytokine networks (TNF‑α, IL‑1, IL‑6, IL‑17) and the gut–bone axis as therapeutic frontiers (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 4-6).
- Mechanotransduction: Osteocytes are “master regulators”; loading suppresses sclerostin enabling Wnt‑mediated formation; unloading increases sclerostin/RANKL, coupling disuse with resorption (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3).
- Denosumab rebound biology: in situ mapping supports that bone-surface osteoprogenitors (Tnfsf11+; Mmp13+) and osteocytes coordinate osteoclastogenic “hotspots,” explaining the clinical rebound if anti‑resorptive blockade is withdrawn without bridging therapy (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26).

Relevant statistics and data
- Diagnostic threshold and burden: WHO T‑score ≤ −2.5 SD defines osteoporosis; global burden is substantial with major regional cost estimates in the US, EU, and Asia Pacific highlighted (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 1-2).
- Serum markers: Meta‑analysis indicates the OPG/RANKL ratio is significantly lower in osteoporosis versus controls, supporting its role in bone turnover assessment (URL: https://doi.org/10.1186/s13018-023-04179-5; Nov 2023) ( is not available; note: within provided context, meta‑analysis summary is beyond the available citation IDs—so detailed numeric reporting is limited).

Gene/protein annotations with ontology terms
- TNFSF11 (RANKL): GO:0042535 positive regulation of tumor necrosis factor superfamily cytokine production; GO:0030316 osteoclast differentiation; located in extracellular region; expressed by osteoblasts/osteocytes (CL:0000064/CL:0000182) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4).
- TNFRSF11B (OPG): GO:0035631 OPG ligand activity; extracellular region; decoy receptor reducing osteoclastogenesis (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4).
- SOST (sclerostin): negative regulation of canonical Wnt signaling (GO:0090090); extracellular region; osteocyte source (CL:0000182) (elahmer2024mechanisticinsightsand pages 2-3).
- CTNNB1 (β‑catenin): canonical Wnt signaling (GO:0060070), nucleus/cytosol (GO:0005634/GO:0005829) in osteoblasts (CL:0000064) (elahmer2024mechanisticinsightsand pages 2-3).
- NFE2L2 (Nrf2)/KEAP1: response to oxidative stress (GO:0006979); nucleus/cytosol; osteoblasts/osteocytes/BMSCs (zhao2025beyondboneloss pages 4-6).
- RUNX2/SP7 (OSX): osteoblast differentiation (GO:0001649); nucleus (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6).
- PPARG: adipocyte differentiation (GO:0045444); drives BMSC adipogenesis (zhao2025beyondboneloss pages 4-6).

Phenotype associations (HP terms)
- HP:0000939 Osteoporosis; HP:0002757 Decreased bone mineral density; HP:0002818 Pathologic fracture; HP:0002937 Osteopenia (early stage) (elahmer2024mechanisticinsightsand pages 1-2, elahmer2024mechanisticinsightsand pages 2-3).

Cell type involvement (CL terms)
- CL:0000092 Osteoclast; CL:0000064 Osteoblast; CL:0000182 Osteocyte; CL:0000739 Th17; CL:0000810 Treg (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8).

Anatomical locations (UBERON terms)
- UBERON:0002371 Trabecular bone; UBERON:0002807 Cortical bone; UBERON:0002371 Bone marrow; UBERON:0002106 Lacuno‑canalicular network (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 25-26).

Chemical entities (CHEBI)
- ROS (CHEBI:26523); calcium ions (CHEBI:29108) in mechanosignaling; anti‑resorptive/anabolic drugs as therapeutic chemical entities (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).

Recent developments and latest research (priority 2023–2024)
- 2024 mechanistic review consolidates RANKL/RANK/OPG and Wnt/sclerostin roles and therapy classes, with global burden and WHO diagnostic thresholds (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 1-2).
- 2024 denosumab rebound mechanism mapped by in situ hybridization, identifying bone-surface Tnfsf11+ osteoprogenitors and reduced OPG priming rebound osteoclastogenesis on discontinuation (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26).
- 2025 review highlights oxidative stress, senescence, mitochondrial dysfunction, and gut–immune axes (SCFAs, Th17/Treg) as integrated contributors and targets (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8).

Limitations
- Some requested quantitative statistics (e.g., precise fracture incidence and prevalence by region) and several human RCT effect sizes on probiotics exceed the available citation IDs in the current context; therefore, only general burden statements and mechanisms from accessible sources are reported (elahmer2024mechanisticinsightsand pages 1-2).

References (URLs and publication dates)
- Elahmer et al., Biomedicines. “Mechanistic Insights and Therapeutic Strategies in Osteoporosis” (Published Jul 23, 2024). URL: https://doi.org/10.3390/biomedicines12081635 (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).
- Zhao et al., Biomedicines. “Beyond Bone Loss: A Biology Perspective…” (Published Jun 2025). URL: https://doi.org/10.3390/biomedicines13061443 (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4, zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 18-20).
- El‑Masri et al., Bone Research. “Mapping RANKL- and OPG-expressing cells…” (Published Oct 2024). URL: https://doi.org/10.1038/s41413-024-00362-4 (elahmer2024mechanisticinsightsand pages 25-26).

References

1. (elahmer2024mechanisticinsightsand pages 2-3): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

2. (zhao2025beyondboneloss pages 4-6): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

3. (zhao2025beyondboneloss pages 2-4): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

4. (elahmer2024mechanisticinsightsand pages 25-26): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

5. (zhao2025beyondboneloss pages 6-8): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

6. (elahmer2024mechanisticinsightsand pages 1-2): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

7. (zhao2025beyondboneloss pages 18-20): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.